Philadelphia, PA (PRWEB) May 16, 2012
The Sidney Kimmel Foundation for Cancer Research has selected the 2012 recipients for the Kimmel Scholar Program. Fifteen research scientists and medical doctors from across the United States will receive two year grants totaling $200,000 under the Foundation's on-going Kimmel Scholar program. This year's selection brings the total to 217 talented cancer researchers who have been provided with grant money since the Foundation's inception.
The Kimmel Scholar Awards were created to advance the careers of gifted, young scientists involved in cancer research. Those selected are chosen for demonstrating the greatest promise and innovation in their work, must be in the early stages of their research career, and have not progressed far enough to have received major grants from the National Cancer Institute or other funding sources.
Sidney Kimmel, the organization's founder, chairman of The Jones Group Inc., and president of Sidney Kimmel Entertainment, meets each year with the Foundation's medical advisory board and observes as the esteemed group of leading cancer doctors narrows down the applicants from a pool of approximately 150. Since 1997 Sidney Kimmel has contributed more than $550 million to cancer centers and cancer research and another $100 million to the arts and Jewish continuity. Kimmel is a member of Warren Buffett's Giving Pledge, having already committed more than half of his net worth to charitable causes.
Many of the exceptional young scientists who have their careers "jump started" by the Sidney Kimmel Foundation for Cancer Research go on to receive millions of dollars in funding from the NCI and NIH and make significant contributions to the field of cancer research. Many report that they might never have achieved such success without first receiving a Kimmel grant.
The recipients for 2012 are:
Eric Bennett, Ph.D., University of California, San Diego
Targeting ubiquitin-proteasome system control of cellular redox homeostasis function
*Trever Bivona, M.D., Ph.D., University of California, San Francisco
Discovery of rational companion therapeutic targets to optimize molecularly-targeted cancer therapy
*Ping Chi, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
Understanding and targeting the oncogenic lineage-specific transcription factor-ETV1-in gastrointestinal stromal tumor (GIST)
Kevin Corbett, Ph.D., Ludwig Institute for Cancer Research and University of California, San Diego
Mechanisms and regulation of homologous recombination in meiosis
Boyi Gan, Ph.D., The University of Texas, M.D. Anderson Cancer Center
Targeting genetic and metabolic networks in renal cell carcinoma
Ekaterina Grishchuk, Ph.D., University of Pennsylvania
Linking the spatial patterns of mitotic phosphoregulation and chromosomal instability in cancer cells
Andre Hoelz, Ph.D., California Institute of Technology
Structural and functional analysis of macromolecular machines in chromatin biology and carcinogenesis
*Jason Huse, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
Investigating miRNA networks that promote proneural gliomagenesis
*Chrystal Louis, M.D., Ph.D., Baylor College of Medicine
Enhancing antitumor activity of cytotoxic t cells used to treat nasopharyngeal carcinoma
Li-Fan Lu, Ph.D., University of California, San Diego
Unveiling molecular mechanisms underlying miR-146a-dependent T-reg cell-mediated TH1 regulation as new targets for anti-cancer therapy
*Sanaz Memarzadeh, M.D., Ph.D., University of California, Los Angeles
Progesterone signaling as a regulator of hormone sensitivity in the endometrial tumor microenvironment
Ji-hye Paik, Ph.D., Weill Cornell Medical College
Function of FoxO in EGFR-targeted gliomas
Dong Wang, Ph.D., University of California, San Diego
Develop novel anticancer drugs targeting DNA damage processing pathways
Zhibin Wang, Ph.D., Johns Hopkins University
Abnormal epigenetic codes mediated by DNMT1 and NuRD/Mi-2 complex in cancer cells
*Elizabeth Wick, M.D., Johns Hopkins University, Kimmel Cancer Center
Defining enterotoxigenic bacteriodes fragilis induced genetic alterations in colorectal cancer
- Translational Scholars
The Foundation is particularly interested in helping physicians who are engaged in research which can rapidly be translated into benefits for patients with cancer. This year six of the fifteen awards have been designated for such "Translational Research."
The Sidney Kimmel Foundation for Cancer Research has also funded four cancer centers at San Diego, Memorial Sloan-Kettering Cancer Center, Thomas Jefferson University and Johns Hopkins University. The gift to Johns Hopkins, $150 million, is the largest gift ever received by that institution. In the area of arts and culture, The Kimmel Foundation has supported the Kimmel Center for the Performing Arts and National Museum of American Jewish History in Philadelphia as well as the United States Holocaust Memorial Museum in Washington D.C., among others. For more information visit http://www.kimmel.org.
# # #